Oura’s $625 Million Counsel Health Deal Puts a Bigger Healthcare Business Within Reach -( $DGX $DXCM $OURA )

The Smart Ring Is Becoming the Front Door

Oura’s next growth engine may be less about selling another ring and more about what happens after the ring notices something worth discussing. The smart-ring maker agreed on November 10 to acquire Counsel Health, an AI-native primary-care company, for $625 million in cash, subject to purchase price adjustments. The transaction, expected to close before the end of 2026, would combine Oura’s continuous biometric tracking with Counsel’s medical AI and on-demand physicians. The strategic ambition is straightforward: move from explaining health signals to helping members act on them. That is a substantial promotion for a device small enough to disappear beneath a winter glove. For many watching the convergence of artificial intelligence, wearables and healthcare, the attraction is not simply another application of AI. It is the possibility of building a recurring relationship around something considerably more durable than a hardware upgrade cycle: a person’s changing health needs. Oura is pursuing that opportunity with meaningful operating momentum. Its preliminary results show fiscal fourth-quarter revenue of $533 million, up 153% from a year earlier, and approximately $1.75 billion in fiscal 2026 revenue, up 92%. The company also reported $87 million of fourth-quarter adjusted EBITDA, representing a 16% margin. These figures remain unaudited and subject to the completion of its year-end close. The combination makes the acquisition more compelling. Oura is not merely buying a new narrative. It is using a rapidly expanding business to pursue a larger one.

A $1.75 Billion Business With Room Beyond Hardware

The bullish case begins with a distinction that can get lost in the wearable-device aisle: selling a product and building a daily habit are different businesses. Oura’s September SEC registration statement offers evidence that it has achieved more than an occasional relationship with its customers. As of June 30, 2026, the company reported:

• 5.0 million paid members across 56 markets.
• Approximately 85% weighted-average 12-month paid-member retention.
• A daily-active-user-to-monthly-active-user ratio of approximately 65%.
• Median ring wear of approximately 23 hours a day during its fiscal third quarter.
• More than 3.5 app openings per day, on average, among paid members during the first three quarters of fiscal 2026.

Those measures matter because a healthcare platform needs more than an impressive sensor. It needs people to keep using it. A device worn almost continuously can develop a longitudinal picture of sleep, activity and physiological patterns. An application opened repeatedly has opportunities to explain those patterns and connect members with additional services. Counsel potentially adds the next step: access to clinical guidance when information alone is insufficient. Oura’s acquisition announcement subsequently cited more than six million members. That broader membership figure should not be treated as interchangeable with the SEC filing’s earlier, specifically defined paid-member count. Even with that distinction, the business has assembled a substantial audience for its next layer of services. The ring earns the invitation. The platform has an opportunity to earn the continuing relationship.

Why Counsel Health Changes the Economics

Counsel brings a physician-supervised care model rather than a stand-alone chatbot with unusually confident bedside manners. Its platform uses specialized AI agents for functions including medical history-taking, guideline retrieval, records review and emergency detection. Members can add a board-certified physician to the conversation, with clinicians able to provide diagnoses, prescriptions and referrals where appropriate. Counsel also supplies physicians with an interface that brings together medical records and longitudinal health information. The proposed combination therefore addresses a familiar weakness in consumer health technology: a measurement can be interesting without making the next decision easier.

Oura and Counsel plan to expand their existing relationship across three areas:

• Preventive care, using continuous information to help identify changes that warrant attention.
• Acute care, providing guidance and physician access for episodic concerns.
• Specialty and chronic care, supporting ongoing needs including reproductive health, aging and cardiometabolic conditions.

Commercially, the opportunity is to make the membership more useful across more circumstances. If that improves retention, increases adoption of additional services or supports stronger enterprise relationships, Oura could capture more value from an audience it has already acquired. Those are potential benefits, not reported acquisition returns. But the logic is appealing: a business that already knows how to get onto someone’s finger is buying a way to become more useful when that person needs help.

Early Feedback Gives the Strategy a Foothold

The acquisition does not begin with two companies meeting for the first time at the closing dinner. Oura and Counsel already have an operating partnership, and the announcement includes early feedback from members using the combined experience. According to the companies, more than 90% of surveyed Counsel users said their Oura data helped them obtain better care. Members who saw a Counsel physician rated the experience 4.6 out of 5. These are company-reported satisfaction findings, not independent proof of improved medical outcomes or lower healthcare costs. They nevertheless provide an encouraging indication that members see value in connecting their biometric information with care. That distinction is important. A promising experience is the beginning of a business case, not the end of a clinical argument. For the bullish thesis, however, the initial signal is useful: members appear to appreciate having a next step beyond admiring, or worrying about, a number on a screen.

Dexcom and Quest Show the Platform Already Taking Shape

Counsel is not Oura’s first move beyond the ring. It is the latest piece of a broader effort to connect different categories of health information inside one application. Through its integration with Dexcom (NASDAQ: DXCM), Oura allows eligible U.S. members to view glucose information from the Stelo biosensor alongside sleep, activity, stress and meal-related context. Importantly, the glucose measurement comes from the separate Stelo sensor, not from the ring itself. Oura’s Health Panels offering, developed with Quest Diagnostics (NYSE: DGX), adds another layer. Members can purchase a $99 panel measuring 50 biomarkers, schedule sample collection at more than 2,000 participating Quest locations and receive results through the Oura application, subject to availability restrictions. The architecture is becoming easier to recognize:

1. The ring supplies continuous physiological context.
2. An integrated biosensor adds glucose information.
3. Laboratory testing adds blood-based measurements.
4. Counsel adds medical guidance and access to physicians.

The strategic value lies in the connections. A laboratory result offers one perspective. Weeks of sleep, activity and physiological trends offer another. Bringing those views into a care conversation could make the overall service more useful than a collection of disconnected dashboards. For Dexcom and Quest, the relationships also illustrate how established healthcare companies can participate in consumer-facing platforms without manufacturing the device that first attracts the customer. They are relevant public-market connections, although Oura’s growth should not be mistaken for a quantified earnings catalyst for either partner.

Enterprise Distribution Could Widen the Opportunity

The acquisition also reaches beyond Oura’s existing membership. Counsel serves enterprise partners including health plans, health systems, consumer health organizations and employers. The companies say Counsel will continue working with existing and new partners after the acquisition, with the aim of extending its care model to millions of people outside Oura’s current member base. That creates two possible distribution routes: Oura can introduce care services to its members, while Counsel’s enterprise relationships can bring the combined capabilities to other populations. Oura already describes an ecosystem of more than 1,200 partners, and its partner offering includes custom integrations and dedicated API support. That infrastructure does not guarantee enterprise success, but it suggests the company is building for distribution beyond its own storefront. The advantage could be a business less dependent on persuading each new customer to buy a ring through a conventional retail funnel. The challenge will be turning partnerships into repeatable revenue rather than a handsome collection of logos. Healthcare has never suffered from a shortage of impressive partnership announcements. Consistent execution remains the scarcer commodity.

The Data Advantage Depends on Trust

Continuous information can strengthen personalization, but only if members remain comfortable sharing it. Oura’s SEC filing describes its privacy-first approach and commitment not to share members’ health data without consent. Its published integration guidance also shows that data flows differ by partnership. For example, its Stelo integration imports glucose information into Oura without sending Oura data back to Stelo through that connection. These details become more consequential as the platform expands from wellness insights into physician-supported services. Members need to understand which organization receives their information, what it is used for and which services they have chosen to activate. Oura also identifies the ring, Stelo and Health Panels among products or services eligible for HSA or FSA spending under applicable conditions. That can help connect its consumer offering with established healthcare spending channels, though eligibility is not the same as broad insurance reimbursement. The opportunity is to make a more comprehensive service feel simpler. The obligation is to avoid making the underlying information-sharing more opaque.

A Stronger Story for an Eventual IPO

Oura remains an IPO candidate rather than an established publicly traded stock. Its September 3 SEC filing proposed a Nasdaq listing under OURA. Bloomberg subsequently reported that the company postponed the offering because of uncertainty in the market for new listings, and its company profile continued to identify the IPO as pending on November 13. The proposed symbol should therefore not be confused with an available public-market listing. Counsel Health is also privately held. For many following a potential Oura IPO, the Counsel acquisition changes the central question. The narrower question is how many smart rings Oura can sell. The more interesting question is how much recurring value it can create around an engaged membership once hardware, software, laboratory information and physician access work together. Oura’s SEC filing describes a broader preventive-health opportunity representing more than $90 billion in serviceable addressable spending. That is management’s market estimate, not a revenue forecast. Still, it captures the company’s ambition to compete for spending beyond wearable hardware. If Counsel helps translate that ambition into stronger retention and attractive service economics, a future offering could present a more diversified business than the one originally associated with sleep tracking.

What Has to Go Right

The positive case is substantial, but it does not eliminate the work ahead. Oura must integrate Counsel, maintain care quality, protect sensitive information and demonstrate that expanded clinical services can produce attractive economics. The transaction announcement does not establish Counsel’s stand-alone profitability, the combined platform’s long-term margins or the acquisition’s eventual return. There is also an essential product distinction: Oura states that its ring is not a medical device intended to diagnose, treat, cure, monitor or prevent medical conditions. Clinical decisions belong within the appropriately supervised care service, not inside a sweeping claim about what a wearable can do. The milestones worth watching are practical: adoption of care services, sustained member retention, enterprise expansion, clinical capacity and the cost of delivering the broader offering. Oura’s preliminary financial results also need to be confirmed through its completed reporting process. These are execution questions, not reasons to dismiss the strategy. They are the conditions under which an appealing acquisition becomes a valuable business.

The Bullish Case: A Small Device With a Larger Economic Role

Oura’s proposed Counsel Health acquisition is compelling because it connects two activities that often remain separate: understanding what is happening and deciding what to do next. The company enters that effort with rapid revenue growth, substantial daily engagement and an expanding set of health-data relationships. Counsel adds a pathway from information to physician-supported action, while its enterprise partnerships could broaden distribution beyond Oura’s existing audience. The acquisition does not guarantee that Oura becomes a healthcare platform with superior long-term economics. It does give the company a credible route toward becoming more than a successful wearable brand. The ring may remain the most visible product. The larger business could be the relationship built around it.

The Sources

1. Counsel Health: Oura to Acquire Counsel Health, Advancing Vision for More Connected, Personalized Healthcare
2. SEC.gov: Oura Inc. Form S-1, Filed September 3, 2026
3. Latham & Watkins: Advises Oura in US$625 Million Acquisition of Counsel Health
4. Oura: Introducing Metabolic Health at Oura
5. Oura: How Does the Stelo Glucose Biosensor Work?
6. Oura: Health Panels & Lab Uploads
7. Oura Member Care: Health Panels
8. Oura: Integrations and Collaboration for Partners
9. Oura: Data Sharing With Oura, How Partner Integrations Work
10. Oura: What Products and Services Are FSA/HSA Eligible?
11. Bloomberg: Smart Ring Maker Oura Becomes Latest Company to Delay US IPO
12. Bloomberg: Oura Inc. IPO Status and Company Profile
13. Bloomberg: Dexcom Inc. Company Profile, DXCM
14. Bloomberg: Quest Diagnostics Inc. Company Profile, DGX